+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

26 February 2021

Visiongain has launched a new report Respiratory Inhalers Market Report 2021-2031: Forecasts by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others Respiratory Disease), by Inhaler Type (Standard Pressurized Metered-dose Inhalers, Breath-actuated Pressurized Metered-dose Inhalers, Metered-dose Inhaler with a Spacer, Dry Powder Inhalers, Soft Mist Inhalers, Other Inhaler Type), by Mode of Operation (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices, Other Mode of Operation), by Class (ICS, SABA+ICS, SABA, LABA, LAMA, ULABA, SABA+SAM A, LABA+LAM, A+ICS, SAMA, Other Class) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Respiratory Inhaler Companies AND COVID-19 Recovery Scenarios.

Asthma Is Already An Epidemic, Creating Opportunities for Inhaler Manufacturers
The global charge of asthma, which is already significant both in terms of morbidity and economic costs, appears to grow rapidly when the world becomes westward. The majority of asthma-related deaths in low and middle-income countries. Asthma is the 14th most important disorder in the world in terms of disability years, according to the recent Global Burden of Disease (GBD) study. Asthma should therefore be one of the top priorities of the health ministers of low and middle-income countries when assessing health priorities, assigning resources, and evaluating the potential costs and advantages of public health interventions.

Which Key Players Are Leading the Global Market and how much Share do they Hold?
The global market for respiratory inhalers is ascending and has made significant gains. The players in the respiratory inhalers market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

Discover sales predictions for the global respiratory inhalers market and submarkets
Along with revenue prediction for the overall world market, there are 7 segmentations of the respiratory inhalers market, with forecasts for 5 disease type, 6 inhaler types, 3 Mode Of Operation, 10 class each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth
As per Visiongain analysis, global respiratory inhalers market is estimated to be valued at US$34.58 billion in 2021 and in terms of volume 106 million units in 2021. The market is projected to reach at a market value of US$51.72 billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Why You Should Buy Visiongain Report only?
The report study aims to explore the market drivers, restraints and also market opportunities facing respiratory inhalers product stakeholders in different geographic areas. Also, it identifies trends, gaps, and opportunities in each micro market segment. Finally, this report identifies the major stakeholders, product portfolios, and recent developments in order to draw a competitive landscape for players in this market.

Leading Players in the Market
• AstraZeneca PLC
• Merck KGaA
• Cipla Limited
• GlaxoSmithKline PLC
• Beximco Pharmaceuticals Limited (BPL)
• OMRON Corporation
• Pulmatrix, Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• OPKO Health, Inc.
• Recipharm publ AB
• Vectura Group plc
• Regeneron Pharmaceuticals, Inc.
• Sanofi Pasteur Pharmaceutical
• C.H. Boehringer Sohn AG & Ko. KG
• F. Hoffmann-La Roche Ltd
• Amiko Digital Health
• Merck & Co., Inc

Key Questions Answered by this Report:
• What is the current size of the overall global microbiome therapeutics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall respiratory inhalers market over the next ten years?
• What are the main segments within the overall respiratory inhalers market?
• How much will each of these segments be worth for the period 2021 to 2031?
• How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world respiratory inhalers?
• What is their current status and how will they develop over the next ten years?
• What are their revenue potentials to 2031?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the leading respiratory inhalers? What are their revenues and latest developments?
• What are some of the most prominent human respiratory inhalers currently in development?
• What are the main trends that will affect the world respiratory inhalers market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global respiratory inhalers market evolve over the forecasted period, 2021 to 2031?
• Which drugs can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biologics Market Report 2024-2034

The biologics market is estimated at US$447 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034.

20 November 2023


Visiongain Publishes mRNA Vaccines Market Report 2023-2033

The global mRNA Vaccines market is estimated at US$11,773.3 million in 2023 and is projected to grow at a CAGR of 10.5% during the forecast period 2023-2033.

08 November 2023


Visiongain Publishes Stem Cell Technologies and Applications Market Report 2023-2033

The global Stem Cell Technologies and Applications market is estimated at US$10,059.6 million in 2023 and is projected to grow at a CAGR of 8.7% during the forecast period 2023-2033.

06 November 2023


Visiongain Publishes Neurology Clinical Trials Market Report 2023-2033

The global Neurology Clinical Trials market is valued at US$9,609.2 million in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period 2023-2033.

01 November 2023